Expert: Unmet Need for Accessible, Effective, Tolerable Therapy for Older Patients With R/R DLBCL
December 13th 2022Based on real-world outcomes, there is an unmet need for an effective therapy to be used among patients aged 75 years or older with relapsed/refractory diffuse large B-cell lymphoma.
Read More